Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity (DARWINII)
Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity - DARWINII
Sponsor: Hoffmann-La Roche
Listed as NCT02314481, this PHASE2 trial focuses on Non-small Cell Lung Cancer and remains ongoing. Sponsored by Hoffmann-La Roche, it has been updated 12 times since 2017, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
12 versions recorded-
Jun 2025 — Present [monthly]
Active Not Recruiting PHASE2
-
Sep 2024 — Jun 2025 [monthly]
Active Not Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
-
Jan 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Mar 2022 — Jan 2024 [monthly]
Recruiting PHASE2
▶ Show 7 earlier versions
-
Jan 2021 — Mar 2022 [monthly]
Recruiting PHASE2
-
Jul 2020 — Jan 2021 [monthly]
Recruiting PHASE2
-
Mar 2019 — Jul 2020 [monthly]
Recruiting PHASE2
-
Dec 2018 — Mar 2019 [monthly]
Recruiting PHASE2
-
Jun 2018 — Dec 2018 [monthly]
Recruiting PHASE2
-
Jun 2017 — Jun 2018 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jan 2017 — Jun 2017 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Hoffmann-La Roche
- University College, London
For direct contact, visit the study record on ClinicalTrials.gov .